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Most common microcytic hypochromic anemias are iron deficiency anemia (IDA) and 𝛽-thalassemia trait (BTT), in which
oxidative stress (OxS) has an essential role. Catalase causes detoxification of H2O2 in cells, and it is an indispensable antioxidant
enzyme. The study was designed to measure erythrocyte catalase activity (ECAT) in patients with IDA (10) or BTT (21), to relate
it with thalassemia mutation type (𝛽0 or 𝛽+) and to compare it with normal subjects (67). Ninety-eight individuals were analyzed
since September 2013 to June 2014 in Tucumán, Argentina. Total blood count, hemoglobin electrophoresis at alkaline pH, HbA2,
catalase, and iron status were performed. 𝛽-thalassemicmutations were determined by real-time PCR. Normal range for ECATwas
70,0–130,0MU/L. ECATwas increased in 14% (3/21) of BTT subjects and decreased in 40% (4/10) of those with IDA. No significant
difference (p = 0,245) was shown between normal and BTT groups, while between IDA and normal groups the difference was
proved to be significant (p = 0,000). In 𝛽0 and 𝛽+ groups, no significant difference (p = 0,359) was observed. An altered ECAT was
detected in IDA and BTT. These results will help to clarify how the catalase activity works in these anemia types.
1. Introduction
Normal erythrocytes are protected against potentially dan-
gerous combination of oxygen and iron (hemichromes and
heme associated iron) for extremely efficient endogenous
mechanisms, such as superoxide dismutase (SOD), catalase,
glutathione peroxidase (GPx), reduced glutathione, and vita-
min E. Microcytosis is the physiological consequence of
reduced hemoglobin content in the red blood cell (RBC) due
to a synthesis defect of globin chains or heme [1]. Experi-
mental data in mice showed that the mitotic events during
differentiation are associated with a substantial reduction in
the mean corpuscular volume (MCV) [2]. In addition to
morphological, biochemical, and metabolic changes, small
cell erythrocytes are characterized by shorter survival, being
the oxidative damage to RBCmembrane, one of the underly-
ing mechanisms responsible [3].
Microcytosis is defined by MCV lower than 80 fL and
hypochromia through mean corpuscular hemoglobin lower
than 27 pg. Hypochromicmicrocytic anemiamay result from
an iron deficiency (iron deficiency anemia), a defect in the
globin genes (hemoglobinopathies or thalassemia), a defect
in heme synthesis (sideroblastic anemia), or a defect in
iron availability and acquisition by erythroblast (anemia of
chronic disease).
According to World Health Organization (WHO), the
primary cause of anemia is iron deficiency, especially in
pregnant women and children [4]. Regarding hemoglo-
binopathies, at present, about 5% of world population
is carrier of a potentially pathological hemoglobin gene.
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Beta- (𝛽-) thalassemia is the most common hemoglobinopa-
thy in theMediterranean basin, theMiddle East, andAsia [5].
Accordingly, in Argentina, 𝛽-thalassemia is the most com-
mon inherited anemia [6–8]. Therefore, the most frequent
hypochromic microcytic anemias are iron deficiency anemia
and 𝛽-thalassemia.
There are two molecular forms of 𝛽-thalassemia, 𝛽+
thalassemia in which a small amount of 𝛽-globin chains
are detectable and 𝛽0 thalassemia, in which they are unde-
tectable. Till this day there are over 200 gene mutations
capable of producing thalassemia phenotypes [9]. Clinically,
𝛽-thalassemia is classified as minor (asymptomatic) or major
(severe anemia), depending on the mutation responsible for
this alteration is present in heterozygous or homozygous
state. There is also a moderate clinical features syndrome
known as thalassemia intermedia (homozygous or double
heterozygous). In 𝛽-thalassemia, as a result of 𝛽-chains
decrease, a relative alpha- (𝛼-) chains excess occurs [10].
Free 𝛼-chains are unable to form viable tetramers and
precipitate in RBC precursors in bone marrow forming
inclusion bodies called hemichromes. They are responsible
for the large intramedullary destruction of erythroblasts
and therefore for ineffective erythropoiesis in 𝛽-thalassemia
[11]. Hemichromes also precipitate in membrane of mature
RBC and cause changes in its structure which induce lipid
peroxidation and exposure of anionic phospholipids, which
together leads to premature clearance by the spleen [12].
In both, erythroid precursors and mature RBCs, free iron
resulting from heme denaturation produces damage to lipids
membrane, cellular proteins, or DNA. Free iron is toxic
because it triggers Fenton reaction in which free radicals are
formed, increasing cellular oxidative stress (OxS) due to reac-
tive oxygen species (ROS) production, such as superoxide,
hydrogen peroxide (H2O2), and hydroxyl radicals [13].
Several studies have evaluated the oxidant and antiox-
idant status in thalassemia major and intermedia [14, 15],
and in severe 𝛽-thalassemia it is difficult to evaluate the role
played by the antioxidant enzymes because of the relevant
proportion of normal red cells due to multiple transfusions.
Furthermore little is known about the oxidative status in 𝛽-
thalassemia trait (BTT) subjects and its relationwith different
𝛽-thalassemia mutations. Such assessment is important due
to the large genotypic and phenotypic heterogeneity of
different populations.
The antioxidant system has been proposed as a biomarker
of OxS throughmeasuring detoxifying enzymes such as cata-
lase [16]. The enzyme was first discovered by Louis Jacques
Thenard in 1818. It is an intracellular enzyme constituted by
four polypeptide chains with four heme-porphyrin groups.
The human catalase gene (CAT, NCBI Gene ID: 847) is local-
ized on the short arm of chromosome 11 (11p13) NM 001752.3
and NP 001743.1. Catalase is responsible for detoxification of
H2O2 in cells [15]. Decreased activity of catalase may lead
to increased H2O2 concentration and damage of oxidation
sensitive tissues that may contribute to the manifestation of
various diseases such as diabetes mellitus and anemia [17].
Iron deficiency affects activity of many iron-dependent
enzymes (like catalase), and in iron deficiency anemia (IDA)
RBCs are more susceptible to oxidation. RBCs from IDA
subjects lyse more readily than normal cells on in vitro
exposure to H2O2 [18], suggesting some defect in the pro-
tection mechanism of iron-deficient RBCs against oxidant
damage. Increased hemoglobin autoxidation and subsequent
generation of ROS can account for the shorter RBC lifespan
and other pathological changes associated with IDA [19].The
literature offers contradictory and limited data on oxidative
stress and antioxidant defense in patients with IDA, and
increased [20] and decreased catalase activity [21] have been
reported.
The present study was designed to measure catalase
activity in individuals suffering from some of the most
common microcytic hypochromic anemia, that is, IDA or
BTT, and to compare it with normal subjects. It was also
proposed to relate the type of 𝛽-thalassemia mutation with
the catalase activity.
2. Materials and Methods
Design. A descriptive cross-sectional study was conducted.
Subjects. The sample consisted of 31 patients who attended
Instituto de Bioquı́mica Aplicada (Tucumán, Argentina), for
the diagnosis of hereditary anemia during the period of
September 2013 up to June 2014. Sixty-seven normal individ-
uals, whose participation was voluntary, were also included.
Blood was drawn and placed in two different tubes, one
containing K2-EDTA anticoagulant and the other without
anticoagulant with the purpose of obtaining serum.
Inclusion Criteria. Patients diagnosed with 𝛽-thalassemia
minor or iron deficiency anemia and normal subjects that
needed to be older than 1 year old were included.
Exclusion Criteria. People under vitamin intake, people who
smoke, with diabetes, coronary heart disease, rheumatoid
arthritis, dyslipidemia, hypertension, malignancy, chronic
liver disease, and renal dysfunction, and patients under iron
therapy during 21 days prior to analysis or who have received
transfusions in the last three months were excluded.
Hematological Studies. Total blood count was performed in
hematology analyzer Sysmex KX-21N (Kobe, Japan). The
diagnosis of the 𝛽-thalassemia trait was performed by cellu-
lose acetate hemoglobin (Hb) electrophoresis at alkaline pH
and HbA2 quantification by microcolumn chromatography
(BioSystems, Barcelona, Spain). IDA diagnosis was made
by determining serum iron, total iron binding capacity
(TIBC), and transferrin saturation (SAT) through colorimet-
ricmethod (Wiener Lab, Rosario, Argentina). SAT lower than
16% was considered diagnostic of IDA.
Erythrocyte Catalase Activity (ECAT). The enzyme was ana-
lyzed in K2-EDTA anticoagulated whole blood using Góth
technique [22]. Absorbance (𝐴) of the yellow complex
of molybdate and hydrogen peroxide was measured at
405 nm against blank 3. Sample contained 1,0mL substrate
(65 𝜇mol/mL H2O2 in 60mmol/L sodium-potassium buffer
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pH 7,4) and 30 𝜇L hemolysate, and after 60 seconds the enzy-
matic reaction was stopped by adding 1,0mL of 32,4mmol/L
ammonium molybdate. Blank 1 contained 1,0mL substrate,
1,0mL molybdate, and 30 𝜇L hemolysate; blank 2 contained
1,0mL substrate, 1,0mLmolybdate, and 30𝜇L buffer; blank 3
contained 1,0mL buffer, 1.0mL molybdate, and 30 𝜇L buffer.
One unit of catalase decomposes 1 𝜇mol of H2O2 in 1 minute
under these conditions and it is related to 1 L of whole blood.
Catalase activity was expressed in Mega Units/L (MU/L) and
was calculated with the following formula:
Erythrocyte catalase activity [MU/L]
=
[𝐴 (blank 1) − 𝐴 (sample)] × 4,26 × 100
𝐴 (blank 2) − 𝐴 (blank 3)
.
(1)
Molecular Analysis. Characterization of 𝛽-thalassemic muta-
tions was realized by real-time PCR. Genomic DNA isola-
tion was performed with High Pure PCR Template Prepa-
ration Kit (Roche Diagnostics). PCR, dissociation curves,
and subsequent analysis were executed on the LightCycler
2.0 (Roche) equipment, simultaneously measuring signals
from two different fluorophores. Primers were designed to
amplify a 587 bp region of 𝛽-globin gene: Forward Primer,
5󸀠-gctgtcatc act acctca tag-3󸀠; Reverse Primer, 5󸀠-gct gcaagt-
caccactca g-3󸀠. Two combinations of hybridization probes
labeled with different fluorophores were used [23].
Statistical Analysis. Results were analyzed using SPSS 21.0
statistical program. The results were reported as Media ±
Standard Deviation. For comparison Student 𝑡-Test and
ANOVA were used. A significance level of p < 0.05 was
adopted. The influence of iron serum on catalase values,
independent of the group (normal, IDA, or BTT), was
evaluated by simple regression analysis.
3. Results
Ninety-eight individuals were studied of which 67 were nor-
mal (N group), 21 with 𝛽-thalassemia trait (BTT group), and
10 with iron deficiency anemia (IDA group). Table 1 shows
the results for catalase activity, hematological parameters, and
iron status in all BTT and IDA patients. Subjects were divided
according to age: children (≤12 years), adolescents (13–18
years), adults (19–59 years), and older adults (≥60 years).
ANOVA detected no significant differences (𝑝 = 0,187) in
ECAT between the stated groups.
Five individuals, who were more than 60 years old, were
normal (5/67, 7.5%), 2 𝛽-thalassemia carriers (2/21, 9.5%),
and 2 IDA (2/10, 20%). Only one of these subjects, which
belonged to the normal group, showed increased catalase
activity (139MU/L). Apparently, age has no influence in the
ECAT of this population.
In order to establish the normal range of catalase activity,
5th and 95th percentiles of N group results were determined.
A range from 70,0 to 130,0MU/L was obtained.
Increased catalase activity in 14% (3/21) of BTT subjects
was observed. No significant differences (𝑝 = 0,245) were













Figure 1: Erythrocyte catalase activity in 𝛽-thalassemia minor, iron
deficiency anemia, and normal subjects. 𝑝 < 0,05 between IDA
and N groups. N, normal; IDA, iron deficiency anemia; BTT, 𝛽-
thalassemia trait.
Four IDA individuals (40%) showed decreased catalase
activity. No significant differences between men and women
were detected in all groups. When N and IDA groups were
compared, significant difference (𝑝 = 0,000) was observed,
since the IDA subjects had lower values than N group
(Figure 1).
Table 2 shows the results in N, BTT, and IDA groups
according to sex. Female IDA subjects have significant differ-
ences (𝑝 < 0,05) with normal group in all parameters, except
TIBC. Catalase in male IDA patients did not demonstrate
significant differences (𝑝 > 0,05) when compared with
normal and BTT groups.
The 𝛽-thalassemia mutations detected in order of fre-
quency were codon 39 (C→T) (5 subjects), IVS-I-110 (G→
A) (5 subjects), IVS-I-1 (G→A) (4 subjects), and IVS-I-
6 (T→C) (2 subjects), and in 5 cases the mutation could
not be assigned. The small number of patients for each
group prevented the comparative study between them.There-
fore differences between 𝛽0 (9 subjects; ECAT = 104,6 ±
31,6MU/L) and 𝛽+ (7 subjects; ECAT = 91,8 ± 17,4MU/L)
groups were studied, which were not significant (𝑝 = 0,359).
There was no influence of iron levels on catalase values
(𝑟2 = 0,153) in these samples.
4. Discussion
Oxidative stress is defined as the interruption of balance
between oxidants and reductants within the body, due to
the excess production of peroxides and free radicals. During
the course of metabolism, superoxide anion is converted
to H2O2 by ubiquitous enzyme SOD. Normally H2O2 is
converted to innocuous compounds by the action of catalase
and peroxidase. But if free iron is available, it reacts with
H2O2 to form hydroxyl radicals which are extremely reac-
tive species leading to depolymerisation of polysaccharide,
DNA strand breakage, inactivation of functional proteins,
and other events [24]. Therefore, this imbalance will cause
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P1 3 0,26 64 116,2 13 262 5
P2 14 0,34 103 54,3 25 444 6
P3 76 0,37 118 61,0 33 293 11
P4 44 0,35 101 59,8 29 313 9
P5 43 0,38 117 81,3 43 358 12
P6 15 0,17 38 37,0 31 397 8
Male (4)
P1 1 0,33 97 90,4 15 352 4
P2 1 0,31 89 83,4 18 323 6
P3 11 0,31 79 71,7 25 216 12
P4 63 0,40 115 77,0 32 403 8
BTT group
Female (15)
P1 12 0,35 106 95,3 78 297 26
P2 10 0,33 100 87,3 75 380 20
P3 57 0,37 107 113,9 34 233 15
P4 48 0,39 121 88,8 80 247 32
P5 33 0,37 108 87,9 90 285 31
P6 33 0,36 103 83,5 63 203 31
P7 34 0,34 104 83,6 50 180 28
P8 38 0,38 115 106,2 176 341 52
P9 63 0,38 110 73,0 81 238 34
P10 56 0,36 106 79,8 100 220 45
P11 11 0,35 105 75,2 103 322 32
P12 32 0,37 111 127,9 80 228 35
P13 22 0,35 104 86,5 104 332 31
P14 28 0,37 114 162,2 71 258 28
P15 26 0,34 101 140,1 83 283 29
Male (6)
P1 45 0,39 115 135,4 259 266 97
P2 1 0,32 93 74,4 29 347 8
P3 12 0,38 112 93,4 66 244 27
P4 65 0,47 142 107,3 144 318 45
P5 21 0,40 121 113,3 127 208 61
P6 16 0,41 126 100,0 58 247 23
HTO, hematocrit; HB, hemoglobin; ECAT, erythrocyte catalase activity; Fe, serum iron; TIBC, total iron binding capacity; SAT, transferrin saturation; IDA,
iron deficiency anemia; BTT, 𝛽-thalassemia trait; P, patient.
damage to cellular components and tissues in the body
leading to OxS, and catalase has a role in it.
Kósa et al. [25] revealed a significant decrease in cata-
lase activity of 43 𝛽-thalassemia carriers and attributed it
to catalase protein damage by increased free radicals and
H2O2. Another study reported increased levels of antioxi-
dant enzymes like SOD, catalase, and GPx in RBCs of 𝛽-
thalassemia minor individuals and near normal values of
these enzymes in RBCs of 𝛽-thalassemia major patients
[26]. They concluded that 𝛽-thalassemia minor RBCs react
to increased OxS rising activities of antioxidant enzymes,
while in 𝛽-thalassemia major normal antioxidant enzyme
levels are due to the presence of normal RBCs from multiple
blood transfusions. However, Boudrahem-Addour et al. [27]
observed a significant increase (𝑝 < 0,05) of catalase activity
in 𝛽-thalassemia major and intermedia. The present results,
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Female (6) 20 ± 19 0,31 ± 0,08∗‡ 90 ± 32∗‡ 68,3 ± 27,4∗‡ 29 ± 10∗‡ 344 ± 68‡ 8 ± 3∗‡
Male (4) 19 ± 30 0,34 ± 0,04∗ 95 ± 15∗ 80,6 ± 8,1 22 ± 8∗ 324 ± 79 7 ± 3∗
BTT group
Female (15) 34 ± 17 0,36 ± 0,02† 108 ± 6† 99,4 ± 25,9 84 ± 32 270 ± 56 31 ± 9
Male (6) 27 ± 6 0,39 ± 0,05† 118 ± 16† 104,0 ± 20,4 114 ± 83 272 ± 52 44 ± 32
N group
Female (39) 36 ± 13 0,41 ± 0,02 137 ± 10 96,8 ± 17,5 81 ± 18 301 ± 54 28 ± 11
Male (28) 37 ± 15 0,44 ± 0,02 147 ± 9 93,1 ± 15,4 94 ± 28 282 ± 38 34 ± 11
∗𝑝 < 0,05 between IDA and N groups by sex; †𝑝 < 0,05 between BTT and N groups by sex; ‡𝑝 < 0,05 between IDA and BTT women.
IDA, iron deficiency anemia; BTT, 𝛽-thalassemia trait; N, normal; HTO, hematocrit; HB, hemoglobin; ECAT, erythrocyte catalase activity; Fe, iron; TIBC, total
iron binding capacity; SAT, transferrin saturation.
in concordance with Gerli et al. [26], showed that some BTT
subjects had increased catalase activity.
Several authors reported increased antioxidant capacity
in BTT individuals, but they do notmeasured catalase activity
[28, 29]. Instead, they used a novel automated measurement
method and Trolox equivalent antioxidant capacity.
In the catalase activity comparison between 𝛽0 and 𝛽+
thalassemia traits, the results were not significant. Also, Kósa
et al. [25] did not find significant differences and concluded
that catalase activity was not related to specific 𝛽-thalassemia
mutations. Furthermore, Labib et al. [30] reported no differ-
ences in total antioxidant capacity of 𝛽0 and 𝛽+ thalassemia
traits.
The normal range of erythrocyte catalase activity was
slightly lower than the one reported by another authors [31],
which was 80,3 to 146,3MU/L. Difference may be due to the
racial characteristics of the population, methodological dif-
ferences, and because they used 2,5th and 97,5th percentiles to
establish normal range. Men and women have no significant
differences in what catalase activity concerns. Instead, Vitai
and Góth [31] found slightly higher values in male subjects.
In this study, like Ondei et al. [29], there was no rela-
tionship between ECAT and iron serum. In 𝛽-thalassemia
major and intermedia, iron excess can lead to organ damage,
especially in liver and heart, and to endocrine dysfunction
[32]. Recent studies have shown the importance of other
markers such as non-transferrin bound iron (NTBI) and
labile plasma iron (LPI) to detect iron excess in thalassemia
patients due to the direct correlation of these markers with
the formation of free radicals [33].
Decreasing serum iron concentration causes insufficient
Hb synthesis with subsequent reduction of erythrocytes pro-
liferation. Iron deficiency also affects the production of other
iron-containing proteins, such as cytochrome, myoglobin,
catalase, and peroxidase. Therefore, a decreased catalase
activity could be anticipated in iron deficiency and has been
corroborated in this study, in agreement with other works
[21, 34, 35]. However, Madhikarmi andMurthy [20] detected
an unexplained increase of catalase activity in IDA, and
Tekin et al. [36] reported no differences in SOD and catalase
activities between IDA patients and controls. Bay et al. [37]
compared antioxidant capacity between IDA and normal
subjects and detected no significant differences.
Increased OxS have been reported in patients with IDA
[3, 21, 35], which occurs primarily in RBC membrane. ROS
membrane surface contributes to deformability alteration
[38] and phosphatidylserine exposure, which have been used
to explain the reduction of RBCs life in IDA [39]. Also,
in BTT an altered oxidative state was reported by some
investigators [28, 30]. Therefore, OxS is present in the most
common hypochromic microcytic anemia, IDA and BTT,
being one of the determining factors of altered catalase
activity. Hypochromic microcytic RBCs of BTT and IDA
individuals have been studied in the past decades and OxS
contribution in reducing the RBCs useful life has been
documented. Previous studies on the catalase activity of
hypochromic microcytic anemia such as IDA and BTT have
reported disagreeing results [20, 21, 25, 26, 34, 35]. In the
present work, catalase activity was decreased in IDA and
increased in some BTT subjects, with no significant differ-
ences between beta-thalassemia mutations.These results will
help to clarify how the catalase activity works in these anemia
types.The lownumber of samples is a limitation of this report.
Probably, the incorporation of a larger number of participants
will allow revealing hidden differences in current work.
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E. Ledesma Achem, and B. A. Issé, “Molecular characteriza-
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